SCHEMBL1332837

SCHEMBL1332837

CCCCC[C@H]1CC[C@H](c2ccc(C(=O)Nc3ccc(-c4ccc5c6c(c7c(c5c4)-c4cc(-c5ccc(NC(=O)c8ccc(-c9ccc([C@H]%10CC[C@H](CCCCC)CC%10)cc9)cc8)cc5C)ccc4C7(C)C)C=CC(c4ccc(OC)cc4)(c4ccc(N5CCN(c7ccc(CCCC)cc7)CC5)cc4)O6)cc3)cc2)CC1

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.32
KMT2A Q03164 3/20 0.32
ALDH1A1 P00352 3/20 0.32
RAB9A P51151 2/20 0.32
NR4A1 P22736 1/20 0.32
MCL1 Q07820 1/20 0.32
HSD17B10 Q99714 3/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
HPGD P15428 2/20 0.31
MEN1 O00255 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
NPC1 O15118 1/20 0.31
KDM4E B2RXH2 1/20 0.31
LMNA P02545 1/20 0.31
TSHR P16473 1/20 0.31
TAAR1 Q96RJ0 1/20 0.31
TP53 P04637 1/20 0.31
MCHR1 Q99705 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1332433 0.90 MCHR1 (0.33) MAPTKMT2AALDH1A1HSD17B10SMN1; SMN2
SCHEMBL15290272 0.87 MAPT (0.35) MAPTKMT2AALDH1A1RAB9ANR4A1
SCHEMBL1334046 0.87 ADORA3 (0.35) KMT2ARAB9AMEN1MCHR1
SCHEMBL12573754 0.86 MAPT (0.35) MAPTKMT2AALDH1A1RAB9ANR4A1
SCHEMBL1332426 0.86 MAPT (0.35) MAPTKMT2AALDH1A1RAB9ANR4A1
SCHEMBL12581582 0.84 ALK (0.34) MAPTKMT2ARAB9ASMN1; SMN2MEN1
SCHEMBL1963611 0.84 ALK (0.34) MAPTKMT2ARAB9ASMN1; SMN2MEN1
SCHEMBL1331933 0.84 NPC1 (0.34) MAPTKMT2AALDH1A1RAB9AHSD17B10
SCHEMBL29910319 0.84 NPC1 (0.34) MAPTKMT2AALDH1A1RAB9AHSD17B10
SCHEMBL1333043 0.84 CTSL (0.34) MAPTKMT2AALDH1A1RAB9ANR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2652552-B9 PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS TRANSITIONS OPTICAL INC (US) 2016-02-17 EP claimed
EP-2652552-B1 PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS TRANSITIONS OPTICAL INC (US) 2015-09-02 EP claimed
US-8545984-B2 Photochromic compounds and compositions TRANSITIONS OPTICAL, INC. (US) 2013-10-01 US claimed
US-20110129678-A1 Photochromic compounds and compositions TRANSITIONS OPTICAL, INC. (US) 2011-06-02 US claimed
EP-2718755-B1 POLARIZING PHOTOCHROMIC ARTICLES TRANSITIONS OPTICAL INC (US) 2024-05-29 EP disclosed
EP-2718754-B1 POLARIZING PHOTOCHROMIC ARTICLES TRANSITIONS OPTICAL INC (US) 2024-01-24 EP disclosed
EP-2969499-B1 METHOD OF PREPARING PHOTOCHROMIC-DICHROIC FILMS HAVING REDUCED OPTICAL DISTORTION TRANSITIONS OPTICAL INC (US) 2021-12-08 EP disclosed
EP-2969468-B1 METHOD OF PREPARING PHOTOCHROMIC-DICHROIC FILMS HAVING REDUCED OPTICAL DISTORTION TRANSITIONS OPTICAL INC (US) 2020-12-23 EP disclosed
EP-2895897-B1 A PHOTOCHROMIC ARTICLE HAVING TWO AT LEAST PARTIALLY CROSSED PHOTOCHROMIC-DICHROIC LAYERS TRANSITIONS OPTICAL INC (US) 2020-03-25 EP disclosed
EP-2652552-B9 PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS TRANSITIONS OPTICAL INC (US) 2016-02-17 EP disclosed
EP-2652552-B1 PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS TRANSITIONS OPTICAL INC (US) 2015-09-02 EP disclosed
US-9030740-B2 Photochromic article having at least partially crossed polarized photochromic-dichroic and fixed-polarized layers TRANSITIONS OPTICAL, INC. (US) 2015-05-12 US disclosed
US-20140078583-A1 Photochromic Article Having At Least Partially Crossed Polarized Photochromic-Dichroic And Fixed-Polarized Layers TRANSITIONS OPTICAL, INC. (US) 2014-03-20 US disclosed
US-8649081-B1 Photochromic article having two at least partially crossed photochromic-dichroic layers TRANSITIONS OPTICAL, INC. (US) 2014-02-11 US disclosed
US-8582192-B2 Polarizing photochromic articles TRANSITIONS OPTICAL, INC. (US) 2013-11-12 US disclosed
US-8545015-B2 Polarizing photochromic articles TRANSITIONS OPTICAL, INC. (US) 2013-10-01 US disclosed
US-8545984-B2 Photochromic compounds and compositions TRANSITIONS OPTICAL, INC. (US) 2013-10-01 US disclosed
US-20120120473-A1 POLARIZING PHOTOCHROMIC ARTICLES TRANSITIONS OPTICAL, INC. (US) 2012-05-17 US disclosed
US-20110279883-A1 POLARIZING PHOTOCHROMIC ARTICLES TRANSITIONS OPTICAL, INC. (US) 2011-11-17 US disclosed
US-20110129678-A1 Photochromic compounds and compositions TRANSITIONS OPTICAL, INC. (US) 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110129678-A1 Photochromic compounds and compositions CRY2, CRY1, PPOX MAPT 573/4885KMT2A 1960/4885ALDH1A1 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.